The in vitro activity of ceftriaxone (Ro 13-9904), a parenteral cephalosporin, was compared with that of other ,8-lactam antibiotics. The compound was less active against Staphylococcus aureus and Staphylococcus epidermidis than was cephalothin or cefamandole, but it was comparable to cefoxitin, cefotaxime, and moxalactam in inhibiting most isolates of S. aureus at 3.1 jig/ml. Ro inhibited Streptococcus pyogenes and Streptococcus pneumoniae at concentrations below 0.25 ,tg/ml, but Streptococcus faecalis required concentrations above 25 ,ug/ml. Neisseria gonorrhoeae and Haemophilus influenzae were inhibited at concentrations similar to those of cefotaxime, less than 0.1 ,ug/ml. Ro 13-9904 was as active as cefotaxime and moxalactam against most Enterobacteriaceae and was the most active agent tested against Proteus, inhibiting all strains tested at 0.006 ug/ml. Ro 13-9904 was slightly less active than moxalactam or cefoxitin against Bacteroides fragilis, requiring more than 100 ,ug/ml to inhibit 90% of isolates, and it was less active than cefoperazone against Pseudomonas aeruginosa. Presence of serum, alteration of pH, and use of various media did not change the inhibitory levels. Bactericidal concentrations were similar to inhibitory levels. Ro 13-9904 was stable to most plasmid-mediated ,B-lactamases, but was hydrolyzed by some Enterobacter, Proteus, and Bacteroides ,B-lactamases of chromosomal origin.
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An increasing number of fl-lactamase-stable cephalosporins have been synthesized within the past few years. However, each has had certain gaps in its overall spectrum of activity, and multiresistant Enterobacteriaceae and nonfermenting aerobic gram-negative bacilli continue to cause serious infections in hospitalized patients. The oxime cephalosporins (5, 7) , as well as moxalactam (6) , have been shown to be active both in vitro and in clinical trials. Thus any new agents which are developed must be evaluated in comparison with these agents.
For these reasons we evaluated ceftriaxone /.-Lactamase activity of all isolates was determined with the Glaxo chromogenic cephalosporin (9) . Enzymes were classified on the basis of hydrolysis of penicillins and cephalosporins (4) . Organisms induced to make ,-lactamase with cephalothin (25 pg/ml) were Enterobacter cloacae, Citrobacter freundii, Morganella morganii, and Bacteroides fragilis. Enzymes were osmotic shockates as described (4) , except for the Escherichia coli, M. morganii, Pseudomonas aeruginosa, and Bacillus cereus enzymes, which were purified according to published methods (4).
RESULTS
The comparative in vitro activities of Ro 13-9904 and other agents are shown in Table 1 0.006->100
1.6->100
1.6->100 0.05->100 0.8->100 1.6->100 0.8->100 0.4->100 0.8->100 0.8->100 1.6->100 12.5->100 Serratia marcescens, P. aeruginosa, and E. cloacae. The MICs and MBCs of representative isolates (five each), tested in brain heart infusion, Trypticase soy, nutrient, and MH media, were within a single dilution of each other in all instances. Comparison of the MICs in MH broth and in MH agar revealed no differences for E. coli, K. pneumoniae, S. marcescens, P. aeruginosa, E. cloacae, P. mirabilis, and S. aureus. Table 3 illustrates the effect of inoculum size on both MICs and MBCs of representative isolates, all of which produced fl-lactamases. At inocula of 103 and 106 CFU, there was no significant difference between MIC and MBC except for P. aeruginosa, in which there was a 32-fold difference between the MIC and MBC at 105 CFU. An 8-to 32-fold difference between MIC and MBC was seen for 10 strains of P. aeruginosa at 10i CFU. There was a definite increase in the MICs and MBCs for all isolates, including the extremely susceptible P. mirabilis, when an inoculum of 107 CFU was used. Indeed, the MIC at 107 CFU of all of these organisms was 128-fold greater or more than the MIC and MBC at 105 CFU.
The MICs and MBCs for five isolates each of E. coli, S. marcescens, K. pneumoniae, E. aerogenes, E. cloacae, and P. aeruginosa differed by less than one tube dilution when tested in MH medium adjusted to pH 6, 7, and 8, indicating that pH had no effect on MICs or MBCs.
We determined that Ro 13-9904 was 93.6% protein bound at a concentration of 1.56 ,tg/ml, 94% bound at 6.25 ,ug/ml, and 91.9% bound at 25 Ag/ml. We determined the MICs and MBCs of representative organisms in 50% human serum. There was no appreciable increase in the MIC or MBC when the assay was performed in serum for most Enterobacteriaceae, but the MIC of P. aeruginosa was eightfold greater.
Killing-curve studies were performed with Ro 13-9904 and other agents against susceptible E. coli, K. pneumoniae, and P. mirabilis. Figure 2 shows a comparison of the effect of Ro 13-9904, cefotaxime, and cefoxitin on a /?-lactamase-producing E. coli. The decrease in CFU was similar for all of the agents, which were present at concentrations twice the MIC. Table 4 shows a direct comparison of Ro 13-9904 and other new compounds against organisms resistant to cephalothin and carbenicillin. Ro showed activity comparable to cefotaxime, ceftizoxime, and moxalactam and was superior, in a number of instances, to cefoxitin and cefamandole. However, Ro 13-9904 did not inhibit isolates resistant to moxalactam or cefotaxime. Table 5 shows that Ro 13-9904 did inhibit all ampicillin-resistant E. coli strains, all cephalothin-and gentamicin-resistant K. pneumoniae strains, all carbenicillin-or cefamandoleresistant Citrobacter strains, carbenicillin-resistant E. cloacae isolates, and all carbenicillin-resistant Morganella, P. rettgeri, and Providencia isolates. It inhibited a few Serratia strains that were resistant to carbenicillin and cefoxitin, but it did not inhibit P. aeruginosa isolates resistant to piperacillin or gentamicin.
,f-Lactamase stability of Ro 13-9904. The stability of Ro 13-9904 to /i-lactamases of various organisms is shown in Table 6 . Ro 13-9904 was not hydrolyzed by the /1-lactamase of S. aureus and underwent miniimal hydrolysis by plasmidmediated TEM-type ,8-lactamase from E. coli or by plasmid-mediated OXA-type ,B-lactamase from Shigella. However, f8-lactamases of Citrobacter, Enterobacter, Pseudomonas, P. vul- Synergy studies. To ascertain the effect of the combination of Ro 13-9904 and other agents, Ro 13-9904 was combined with gentamicin and with carbenicllin and tested against 32 isolates of E. coli, K. pneumoniae, S. marcescens, S. aureus, C. freundii, P. aeruginosa, P. rettgeri, and E. cloacae. Table 7 shows that complete synergy of Ro 13-9904 and gentamicin was demonstrated for only 16% of isolates and 19% of isolates when Ro 13-9904 and carbenicillin were combined. Overall, some degree of synergy was found for 59 and 44% of the isolates tested with either combination. Antagonism was not seen for the carbenicillin-Ro 13-9904 combination. Figure 3 shows the effect of Ro 13-9904 and gentamicin when tested against P. aeruginosa.
DISCUSSION
The last few years have seen the introduction of a large number of cephalosporin antibiotics which have increased the antibacterial spectrum of older agents to include fl-lactamase-producing Enterobacteriaceae and Bacteroides. Cefotaxime (5), moxalactam (6), cefoperazone (8) , and ceftizoxime (2) have been shown to inhibit organisms resistant to cefamandole, cefuroxime, and cefoxitin. Ro 13-9904 has been another addition to this group of potent ,B-lactam antibiotics. In general, this agent has shown activity against most members of the Enterobacteriaceae similar to those of cefotaxime, ceftizoxime, and moxalactam. It was more active against P. mirabilis than other compounds, but some indole-positive Proteus isolates had MICs of 25 Ag/ml, as did some E. cloacae. In both cases this resistance could be correlated with instability to the chromosomally mediated ,B-lactamases of these organisms. This compound was much less active than cefoperazone or piperacillin against P. aeruginosa and was less active than cefoxitin or moxalactam against B. fragilis subsp. fragilis, which contains a f-lactamase-that hydrolyzes
